By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


The Medicines Company 

8 Sylvan Way

Parsippany  New Jersey  07054  U.S.A.
Phone: 973-290-6000 Fax: 973-656-9898


The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland.

Key Statistics

Ownership: Public

Web Site: The Medicines Company
Employees: 500+
Symbol: MDCO


UCB, Inc.  Contract manufacturing of Bivalirudin peptide active ingredient


Company News
The Medicines Company (MDCO) Announces Clive Meanwell, MD, Phd, Chief Executive Officer, Is The Recipient Of The 2016 Dr. Sol J. Barer Award For Vision, Innovation And Leadership 2/5/2016 9:13:16 AM
The Medicines Company (MDCO) To Announce Fourth Quarter And Full Year 2015 Financial Results On Wednesday, February 17, 2016 2/4/2016 10:13:28 AM
The Medicines Company (MDCO) To Participate In Leerink Partners 5th Annual Global Healthcare Conference 2/3/2016 11:10:12 AM
The Medicines Company (MDCO) Completes Divestiture Of Its Hemostasis Portfolio To Mallinckrodt (MNK) 2/1/2016 10:16:33 AM
Mallinckrodt (MNK) Completes Acquisition Of Three Commercial-Stage, Global Specialty Hemostasis Brands From The Medicines Company (MDCO) 2/1/2016 6:59:34 AM
The Medicines Company (MDCO) Advances Clinical Development Of Investigational First-In-Class PCSK9 Synthesis Inhibitor For Atherosclerotic Cardiovascular Disease (ASCVD) 1/11/2016 12:09:28 PM
The Medicines Company (MDCO) to Sell Its Hemostatis Portfolio to Mallinckrodt (MNK) in Deal Worth $410 Million 12/18/2015 7:15:16 AM
The Medicines Company (MDCO) Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published In European Heart Journal- Cardiovascular Pharmacotherapy 12/15/2015 11:33:33 AM
Glenn Sblendorio To Retire As President And Chief Financial Officer From The Medicines Company (MDCO) 12/10/2015 10:28:28 AM
The Medicines Company (MDCO) To Participate In Oppenheimer 26th Annual Healthcare Conference 12/4/2015 10:49:49 AM